Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study

• Published in: Radiation oncology (London, England) England), 2022-07, Vol.17 (1), p.1-119, Article 119
• Main Authors: Mo, Qiuping, Wang, Yongzhen, Shan, JinLan, Wang, Xiaochen
• Format: Article
• Language: English
• Subjects: Adjuvant; Analysis; Breast cancer; Breast neoplasm; Cancer therapies; Care and treatment; Demographics; Diagnosis; Disease; Epidemiology; Health aspects; Health hazards; Health risks; Hormone receptors; Invasiveness; Lumpectomy; Matching; Medical prognosis; Metastasis; Mucinous; Patient outcomes; Patients; Population; Population studies; Population-based studies; Prognosis; Radiation therapy; Radiotherapy; Regression analysis; Regression models; Risk factors; Subgroups; Survival analysis; Tumors; Variables; Women; Womens health
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/s13014-022-02082-7

Purpose Pure mucinous breast cancer is a rare subtype of invasive breast cancer with favorable prognosis, in which the effect of postoperative radiotherapy remains unclear. We aimed to investigate the prognostic value of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy. Methods We conducted a retrospective cohort study to compare the effectiveness of postoperative radiotherapy (RT) and omitting postoperative radiotherapy (non-RT) in patients with first primary T1-2N0M0 (T [less than or equai to] 3 cm) pure mucinous breast cancer who underwent lumpectomy between 1998 and 2015 using the Surveillance, Epidemiology, and End Results (SEER) database. Breast cancer-specific survival (BCSS) was compared between RT and non-RT groups using Kaplan-Meier method and Cox proportional hazards regression model. Propensity score matching (PSM) was carried out to balance cohort baselines. In addition, an exploratory analysis was performed to verify the effectiveness of RT in subgroup patients. Results Of 7832 eligible patients, 5352 (68.3%) underwent lumpectomy with postoperative RT, 2480 (31.7%) received lumpectomy without postoperative RT. The median follow-up duration was 92 months. The median age was 66 years in the RT group and 76 years in the non-RT group.The 15-year BCSS was 94.39% (95% CI, 93.08% to 95.35%) in the RT group versus 91.45%(95% CI, 88.93% to 93.42%) in the non-RT group (P < 0.001). The adjusted hazard ratio for BCSS was 0.64 (95% CI, 0.49 to 0.83; P = 0.001) for RT group versus non-RT group. After propensity score matching, similar results were yielded. Adjuvant RT reduced the 15-year risk of breast cancer death from 7.92% to 6.15% (P = 0.039). The adjusted hazard ratio for BCSS were 0.66 (95%CI, 0.47 to 0.92; P = 0.014) for RT group versus non-RT group. The benefit of RT was well consistent across subgroup patients. Conclusion Among women with T1-2N0M0 (tumor size [less than or equai to] 3 cm) pure mucinous breast cancer, the addition of RT after lumpectomy was significantly associated with a reduced incidence of breast cancer death compared with non-RT, and the magnitude of benefit may be modest. This suggests that postoperative RT is recommended in the treatment of localized pure mucinous breast cancer. Keywords: Breast neoplasm, Radiotherapy, Adjuvant, Lumpectomy, Prognosis, Mucinous